Jun-Xia Cao, et al. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies. Cytotherapy, 2019; 00: 1-13
Shannon LM et al .Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia N Engl J Med 2018; 378:439-448
Chimeric antigen receptor T cells for ALL. Amrolia PJ, Pule M. Lancet. 2015;385(9967):488
Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21:4062-4072
Terry J Fry, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine 2017; doi:10.1038/nm.4441
Topp, M.S. et al. Phase II trial of the anti-CD19 bispecific T cell–engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134–4140 (2014)
Lee, D.W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015)
Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014)
Raponi, S. et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk. Lymphoma 52, 1098–1107 (2011)
Grupp, S.A. et al. Durable remissions in children with relapsed/refractory ALL Treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood 126, abstr. 681 (2015)
Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165–1174 (2013)
Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123-2138
Berdeja JGLY, Raje N, Munshi N, et al. Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-Bcma CAR T cell therapy. Blood 2017;130 (suppl 1): 740 (abstr).
Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 2018; 36: 2267–80
Cao J, Wang G, Cheng H, et al. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 2018; 93: 851–58
Kang Liu, Guiqin Song, Xin Hu, Yuchuan Zhou, Ying Li, Qiaoling Chen, Gang Feng (2015). A Positive Role of Cytokine-Induced Killer Cell Therapy on Gastric Cancer Therapy in a Chinese Population: A Systematic Meta-Analysis. Med. Sci. Monit. 2015; 21:3363-3380. Retrieved from: https://DOI: 10.12659/MSM.894504
Joon Hyeok Lee, Jeong-Hoon Lee, Young-Suk Lim, Jong Eun Yeon, Tae-Jin Song, Su Jong Yu, Geum-Youn Gwak, Kang Mo Kim, Yoon Jun Kim, Jae Won Lee, Jung-Hwan Yoon (2015). Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology 2015; 148: 1383-1391. Retrieved from: http://dx.doi.org/10.1053/j.gastro.2015.02.055
Zhou et al (2018). Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis. Cancer Management and Research 2018; 10: 5363-5372. Retrieved from: https://www.dovepress.com/terms.php
Xiang Wang, Song Tang, Xiang Cui, Jinwei Yang, Chunyu Geng,Cong Chen, Ning Zhou, Yumin Li (2018). Cytokine-induced killer cell/dendritic cell–cytokine-induced killer cell immunotherapy for the postoperative treatment of gastric cancer: A Systematic Review and Meta-Analysis. Medicine 2018; 97:36 (e12230). Retrieved from: http://dx.doi.org/10.1097/MD.0000000000012230
Jian Zhang, Huizhong Li, Dazhi Gao, Baofu Zhang, Maojin Zheng, Mingyin Lun, Mengxue Wei, Rui Duan, Maomao Guo, Jiajun Hua, Qian Liu, Jin Bai, Hui Liu, Junnian Zheng & Hong Yao (2018) A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE, Cancer Biology & Therapy, 19:6, 475-483, Retrieved from: https://doi.org/10.1080/15384047.2018.1433501
Mosin´ ska P, Gabryelska A, Zasada M and Fichna J (2017) Dual Functional Capability of Dendritic Cells – Cytokine-Induced Killer Cells in Improving Side Effects of Colorectal Cancer Therapy. Front. Pharmacol. 8:126. doi: 10.3389/fphar.2017.00126
CONGCHEN, YIN-HUAMA, YA-TINGZHANG, FANZHANG, NINGZHOU, XIANGWANG, TAOLIU & YU-MINLI (2018) Effect of dendriticcell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis. Cytotherapy, 2018; 20:975-989. Retrieved from: https://doi.org/10.1016/j.jcyt.2018.06.002
Li Xua, Jun Wanga, Yuhree Kim, Ze-yu Shuang, Yao-jun Zhanga, Xiang-ming Lao, Yong-qiang Li, Min-shan Chen, Timothy M. Pawlik, Jian-chuan Xiab, Sheng-ping Li, and Wan-yee Lau (2016). A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. ONCOIMMUNOLOGY 2016, VOL. 5, NO. 3, e1083671 (8 pages). Retrieved from: http://dx.doi.org/10.1080/2162402X.2015.1083671
JINGTING JIANG, NING XU, CHANGPING WU, HAIFENG DENG, MINGYANG LU,MIN LI, BIN XU, JUN WU, RONGCHAO WANG, JUN XU and PETER NILSSON-EHLE (2006). Treatment of Advanced Gastric Cancer by Chemotherapy Combined with Autologous Cytokine-induced Killer Cells. ANTICANCER RESEARCH 26: 2237-2242 (2006).
Yunqing Xie, Lijie Huang, Luchuan Chen, Xiaowei Lin, Li Chen and Qiuhong Zheng (2017). Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment. World Journal of Surgical Oncology (2017) 15:209. DOI 10.1186/s12957-017-1278-1
Yan Wang, Benji Lv, Ke Li, Anqi Zhang, Hong Liu (2017). Adjuvant immunotherapy of dendritic cells and cytokine-induced killer cells is safe and enhances chemotherapy efficacy for multiple myeloma in China: a meta-analysis of clinical trials. Drug Design, Development and Therapy, 2017; 11: 3245-3256. Retrieved from: http://dx.doi.org/10.2147/DDDT.S146959
Yuhan Zhang, Shuaibing Wang, Beibei Yang, Su Lu, Yiyi Du, Hong Liu (2019). Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients. Cancer Biol Med 2019. doi: 10.20892/j.issn.2095-3941.2018.0378.
Frederic Carsten Schmeel, Leonard Christopher Schmeel, Sanna-Marie Gast and Ingo G. H. Schmidt-Wolf (2014). Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies. Int. J. Mol. Sci. 2014, 15, 14632-14648; doi:10.3390/ijms150814632. Retrieved from: https://doi:10.3390/ijms150814632
